2022. Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s73. DOI:https://doi.org/10.25251/skin.6.supp.73.